A stellar example is the use of Adalimumab in the Novel Therapies for Resistant FSGS (FONT) trial based on experimental and clinical data supporting the role of tumor necrosis factor α (TNF-α) in the pathogenesis of a wide spectrum of kidney diseases including FSGS [30]. The gene discussed is TNF; the disease is kidney disorder.